Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules
| Autor: | Vicki Rubin Kelley, T. G. Woodworth, J. R. Murphy, Nichols Jc, Terry B. Strom |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Interleukin 2
Lymphoma medicine.drug_class medicine.medical_treatment Recombinant Fusion Proteins Antineoplastic Agents Monoclonal antibody General Biochemistry Genetics and Molecular Biology Autoimmune Diseases medicine Animals Humans Diphtheria Toxin Receptor Immunosuppression Therapy Leukemia biology business.industry Immunotoxins Antibodies Monoclonal Receptors Interleukin-2 General Medicine Immunotherapy medicine.disease humanities Cytokine Immunology Monoclonal biology.protein Cytokines Interleukin-2 Antibody business medicine.drug |
| Zdroj: | Annual review of medicine. 44 |
| ISSN: | 0066-4219 |
| Popis: | With the exception of certain hematologic malignancies, the high affinity interleukin-2 (IL-2) receptor is only transiently expressed during the brief antigen-triggered proliferative burst of lymphocytes. Hence, we wondered whether administration of anti-IL-2 receptor (IL-2R) monoclonal antibody (mAb) or chimeric IL-2 toxins would provide a utilitarian way to achieve immunosuppression aimed directly at activated lymphocytes, or whether this approach could be used to treat IL-2R+ leukemia/lymphoma. Studies in preclinical autoimmune and transplant models indicate that this approach can be effective. The results of open, uncontrolled studies provide preliminary evidence that a chimeric IL-2 toxin is well tolerated at doses that may induce improvement in patients with IL-2R+ leukemia/lymphoma, as well as in patients with refractory rheumatoid arthritis or new-onset diabetes mellitus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|